News

The collaboration aims at leveraging Amunix’s XTEN half-life extension technology in Janssen’s protein and/or peptide therapeutics. Amunix president Volker Schellenberger said XTEN polymer can be integrated with a

The alliance will also focus on commercializing network, thereby enhancing the rate of translating academic research into new medicines. Founding organizations include The Centre for Drug Research and

The study is designed to assess rIX-FP’s safety, efficacy and pharmacokinetic profile in children who previously received treatment. CSL Behring along with its parent company, CSL Limited, is

University of Toronto professor and vice-chair of medicine and University Health Network IPF researcher and consultant respirologist Charles Chan said, "Esbriet really is a game-changer. I am excited

Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and Denmark during the first six months of 2013 and in other states all through

The only approved entirely human monoclonal antibody Ilaris continuously neutralizes interleukin-1 beta thereby inhibiting inflammation. Novartis division head David Epstein said, "When approved, lIaris will provide a new

Hidrox is an ingredient derived from olive polyphenols and the only formulation of organic hydroxytyrosol developed to reduce inflammation. CreAgri founder and CEO Roberto Crea said, "We’ve had

Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics of GMI-1070. The double-blinded study enrolled a total of 76 patients between

The approval was based on safety and efficacy data from two double-blind, randomized, multi-center trials conducted in adults whose OAB symptoms were not managed using anticholinergic treatments. Allergan